2023
Fall-related Injuries and Opioid Administration Among Veterans With Dementia in US Department of Veterans Affairs Community Living Centers
Wang H, Cai S, Caprio T, Goulet J, Intrator O. Fall-related Injuries and Opioid Administration Among Veterans With Dementia in US Department of Veterans Affairs Community Living Centers. Medical Care 2023, 61: 579-586. PMID: 37476853, DOI: 10.1097/mlr.0000000000001889.Peer-Reviewed Original ResearchConceptsFall-related injuriesOpioid Safety InitiativeOpioid administrationCLC residentsVeterans Affairs Community Living CentersAlzheimer's diseasePropensity scoreSafety initiativesMinimum Data Set assessmentsMedication administration dataOpioid use reductionPrescription refill dataCommunity Living CentersMedicare Part D dataNursing home residentsLong-stay residentsPart D dataNonopioid usersOpioid useRefill dataUntreated painHome residentsVA CLCsAdjusted probabilityCare recordsPatterns of Digoxin Prescribing for Medicare Beneficiaries in the United States 2013-2019
See C, Wheelock K, Caraballo C, Khera R, Annapureddy A, Mahajan S, Lu Y, Krumholz H, Murugiah K. Patterns of Digoxin Prescribing for Medicare Beneficiaries in the United States 2013-2019. American Journal Of Medicine Open 2023, 10: 100048. PMID: 38213879, PMCID: PMC10783702, DOI: 10.1016/j.ajmo.2023.100048.Peer-Reviewed Original ResearchDigoxin prescriptionDigoxin useNew heart failure therapiesGeneral medicine physiciansHeart failure therapyMedicare Part D dataPart D dataDigoxin prescribingFailure therapyPrescriber characteristicsMedicine physiciansMedicare beneficiariesPrescribersLikely maleLogistic regressionDigoxinNew prescribersPrescriptionRecent dataCardiology
2017
Early National Dissemination of Abiraterone and Enzalutamide for Advanced Prostate Cancer in Medicare Part D
Caram M, Borza T, Min H, Griggs J, Miller D, Hollenbeck B, Mukherjee B, Skolarus T. Early National Dissemination of Abiraterone and Enzalutamide for Advanced Prostate Cancer in Medicare Part D. JCO Oncology Practice 2017, 13: jop.2016.020206. PMID: 28628393, PMCID: PMC5555032, DOI: 10.1200/jop.2016.020206.Peer-Reviewed Original ResearchConceptsMetastatic castration-resistant prostate cancerHospital referral regionsProstate cancerMetastatic castration-resistant prostate cancer treatmentCastration-resistant prostate cancerProvider specialtyAdvanced prostate cancerMedicare Part DProstate cancer incidenceFood and Drug AdministrationMinority of providersYears of ageEnzalutamide prescriptionsMultilevel regression modelsMedicare Part D dataPart DEnzalutamideAbirateroneMedical oncologistsMedical oncologyEarly disseminationTreated menPart D dataCancer incidenceWorkforce densityEarly national dissemination of abiraterone and enzalutamide for advanced prostate cancer in Medicare Part D.
Caram M, Borza T, Min H, Griggs J, Miller D, Hollenbeck B, Mukherjee B, Skolarus T. Early national dissemination of abiraterone and enzalutamide for advanced prostate cancer in Medicare Part D. Journal Of Clinical Oncology 2017, 35: 35-35. DOI: 10.1200/jco.2017.35.8_suppl.35.Peer-Reviewed Original ResearchAdvanced prostate cancerHospital referral regionsProstate cancerProvider specialtyAdvanced prostate cancer treatmentProstate cancer incidenceProstate cancer treatmentMedicare Part DEnzalutamide prescriptionsFood & Drug AdministrationMedicare Part D dataEnzalutamideMinority of providersAbirateroneMedical oncologistsOral medicationsMedical oncologyEarly disseminationTreated menPart D dataCancer incidenceDrug AdministrationCancer treatmentMultilevel regression modelsPart D
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply